ARTIVION, INC. (AORT) research
ARTIVION, INC.- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $24.13
- As of
ARTIVION, INC. (AORT): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-07.
As of . Source: SEC EDGAR filings for AORT. Method and limitations.
Share the AORT intelligence card
See AORT live in the terminal
Track AORT's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live AORT terminal, freeActive signals for AORT
- highCONSENSUS_BUY
3 tracked funds increased AORT this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased AORT this 2026Q2, institutional consensus
- mediumNEW_POSITION
RENAISSANCE TECHNOLOGIES LLC new position in AORT
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +3222% to AORT (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +6615% to AORT (2026Q2)
FREE, NO ACCOUNT
Every signal on AORT, as it fires
You are seeing 5 of 16 signals recorded on AORT since 2026-07-24.
The five above landed across 2 days. The other 11 were recorded on 2 other days. 12 of the 16 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AORT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 228903100 · 2026Q2 | $18.6M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 228903100 · 2026Q2 | $9.8M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 228903100 · 2026Q2 | $8.7M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 228903100 · 2026Q2 | $1.5M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AORT
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
AORT against its peers
AORT's operating margin of 7.6% ranks in the 83rd percentile of 20 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-28 and 2026-05-31.
| Metric | AORT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 441M USD | 218M USD | 69 | 20 |
| Gross margin | 64.4% | 64.6% | 50 | 18 |
| Operating margin | 7.6% | -17.5% | 83 | 20 |
| Net margin | 2.2% | -19.1% | 74 | 20 |
| Return on equity | 2.2% | -18.8% | 74 | 20 |
| P / E | 114.9x | n/a | n/a | 3 |
Peers (20): AVNS, IART, BBNX, ENOV, CBLL, INMD, SIBN, QDEL, SSII, ESTA, UFPT, KIDS, DCTH, BFLY, AXGN, SENS, TCMD, NEOG, NPCE, MASS. Left out: LMRI (no annual filing), NHNKF (no annual filing), OSSUY (no annual filing), ALMR (no annual filing), BWAY (period gap). Fiscal periods ending between 2025-12-28 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (AORT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more AORT signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to AORTand get the insider, 13F, options, and confluence read in one view.